Showing results (1-10 of 13) with videos related to
Sort By:
Pageof 2
Clinical Lymphoma, Myeloma & Leukemia|December 25, 2012
High frequencies of response after limited primary therapy for multiple myelomaRaymond Alexanian, Kay Delasalle, Michael WangAmerican Journal of Hematology|June 28, 2005
Thalidomide-dexamethasone as primary therapy for advanced multiple myelomaMichael Wang, Donna M Weber, Kay Delasalle, et al.British Journal of Haematology|June 5, 2003
Thalidomide and dexamethasone for resistant multiple myelomaAthanasios Anagnostopoulos, Donna Weber, Kim Rankin, et al.Bone Marrow Research|June 8, 2012
Curability of multiple myelomaRaymond Alexanian, Kay Delasalle, Michael Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Thalidomide alone or with dexamethasone for previously untreated multiple myelomaDonna Weber, Kim Rankin, Maria Gavino, et al.Seminars in Hematology|March 16, 2004
Thalidomide with or without dexamethasone for refractory or relapsing multiple myelomaRaymond Alexanian, Donna Weber, Athanasios Anagnostopoulos, et al.Seminars in Oncology|April 30, 2003
2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemiaDonna M Weber, Meletios A Dimopoulos, Kay Delasalle, et al.American Journal of Clinical Oncology|June 23, 2011
Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myelomaWeijun Fu, Kay Delasalle, Jialei Wang, et al.Cancer|March 29, 2002
Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of boneRichard B Wilder, Chul S Ha, James D Cox, et al.American Journal of Hematology|August 28, 2007
Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyondYuhong Zhou, Liang Zhang, Jorge Romaguera, et al.Pageof 2